Advertisement

Topics

Clinical Trials About "certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol" RSS

09:55 EST 18th December 2018 | BioPortfolio

We list hundreds of Clinical Trials about "certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol" on BioPortfolio

We have published hundreds of certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol news stories on BioPortfolio along with dozens of certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol Clinical Trials and PubMed Articles about certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol Companies in our database. You can also find out about relevant certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol Drugs and Medications on this site too.

Showing "certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol" Clinical Trials 1–25 of 81

Extremely Relevant

Optimizing Cimzia in Crohn's Patients

The purpose of this study is to determine if increasing the dose and/or dosing frequency of certolizumab pegol (Cimzia) is effective in regaining and optimizing response in patients with moderate to severe Crohn's disease.


Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of certolizumab pegol (CZP) in subjects with active axial spondyloarthritis (axial SpA).


Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

The primary objective of the study is to assess the safety of long term therapy with certolizumab pegol in those subjects participating in study C87085.

Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol when administered without coadministration of methotrexate over the long term in Japanese RA patients who transferred from Study 275-08-003 (NCT00791921), and to evaluate the effects of different dosing regimens on the safety and efficacy of certolizumab pegol in American College of Rheumatology 20% (ACR20) responders who completed Study 275-08-003.

Does Clinical Response Correlate With Serum Certolizumab Levels?

A prospective open label trial of adult patients with active Crohn's disease to determine if plasma concentrations of certolizumab pegol correlate to mucosal healing.

Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab

An open-label multi-center single-cohort study to assess the safety and efficacy of certolizumab pegol for the treatment of signs and symptoms of active Crohn's disease in Greek patients who have previously responded to infliximab but who no longer have a sustained response or became intolerant to infliximab

Evaluation of the Effects of Certolizumab Pegol on Semen Quality in Healthy Male Volunteers

The primary objective of this study is to evaluate the effect of certolizumab pegol (CZP) on the quality of sperm obtained from healthy male volunteers.

Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

The study aims to evaluate the predictability of early response to Certolizumab pegol in combination with Methotrexate at one year in patients with moderate to severe rheumatoid arthritis.

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

This 26-week extension study evaluates the efficacy and safety of certolizumab pegol administered subcutaneously every 4 weeks (dosed at Weeks 16, 20, 24, 28 and 32) in subjects with active Crohn's disease who had no clinical response at Week 6 to induction therapy in the 6-week double-blind main study, C87037 (NCT00291668), but subsequently showed clinical response at Week 14 to repeated induction therapy (dosed at Weeks 8, 10 and 12) in this extension study.

Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)

To compare the bioavailability of a single 400 mg dose of certolizumab pegol solution (2 x 200mg subcutaneous injections) injected either by a pre-filled syringe (reference) or by an auto-injection device (test).

CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)

The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment, intolerant, have medical contraindications or had insufficient response with an authorized conventional therapy, including other authorized biologics.

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Randomized, double-blind, placebo controlled study evaluating the efficacy of certolizumab pegol in the treatment of interstitial cystitis/ bladder pain syndrome.

Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)

The objective of this Named Patient Program (NPP) is to provide continued availability of Certolizumab Pegol (CZP) to adult Rheumatoid Arthritis (RA) patients who participated in the open label studies C87015 (CDP870 015), C87028 (CDP870-028) and C87051 (CDP870-051). Physicians may use the option to continue offering patients CZP treatment or to transition patients off CZP to a standard care regimen.

A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis

This study will evaluate the safety & efficacy of Certolizumab Pegol (CZP) as additional medication to Methotrexate (MTX) in Chinese subjects with Rheumatoid Arthritis. 400 patients will be randomized to receive either CZP + MTX or placebo + MTX. Anticipated time in the study is about 32 weeks.

A Study of the Safety of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

An open ended study in which patients who completed the double-blind study (CDP870-050) are given Certolizumab pegol and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.

The Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis to Assess the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

The purpose of this trial is to assess the affect of Certolizumab Pegol (CZP) treatment on antibody response to T cell-independent and T cell-dependent immunizations using pneumococcal and influenza vaccines.

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate.

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

To investigate the clinical efficacy of certolizumab pegol for fistula closure in Crohn's disease subjects with active draining fistulas.

Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis.

Study to evaluate the efficacy and safety of Bimekizumab compared to Certolizumab Pegol in the treatment of subjects with active ankylosing spondylitis (AS)

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

The current study is designed to measure the corticosteroid-sparing effect of certolizumab pegol using a defined schedule of corticosteroid tapering in subjects with moderate to severe Crohn's disease.

Mucosal Healing Study in Crohn's Disease (CD)

The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.


More From BioPortfolio on "certolizumab pegol certolizumab pegol certolizumab pegol certolizumab pegol"

Advertisement
Quick Search
Advertisement
Advertisement